Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 06/18 04:46:07 am
348.35 CHF   -0.01%
06/17ROCHE HOLDINGS AG  : Deutsche Bank reiterates its Neutral rating
06/17Synlogic, Roche in Bowel-Disease Collaboration
06/17ROCHE  : Syncona CFO to Retire; Three New Executives Named
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott says COVID-19 test demand to grow in 2021

10/21/2020 | 07:42am EDT

Oct 21 (Reuters) - Abbott Laboratories said it expects demand for its COVID-19 tests to grow in 2021 even if a vaccine is developed and for the business to eventually stabilize into a lucrative new franchise.

It made the comments during its quarterly investor update, where it raised its 2020 profit forecast on strong COVID-19 testing revenues and a recovery in its medical device business as patients opt for surgeries they had put off due to the pandemic.

COVID-19 testing, which earned Abbott $881 million in sales in the most recent quarter, will eventually become a stable franchise for Abbott like its influenza tests, Chief Executive Robert Ford said during Abbott's earnings call.

The pandemic is creating new relationships with airports, retailers and doctors offices, which will continue to purchase its tests, he said.

Demand for molecular diagnostic tests may decline once people receive COVID-19 vaccines but antibody tests, which detect past infections, could get a boost, he said.

The company said sales in its medical devices unit rose about 3% from the prior quarter to $3.17 billion, as its cardiovascular and neuromodulation businesses improved. Sales in its diagnostics unit jumped nearly 39% to $2.64 billion.

For an interactive graphic on Abbott's segment sales growth, click here: (https://tmsnrt.rs/35fJzY2)

Abbott has U.S. authorization for several tests including one in August for a $5 portable antigen test called BinaxNOW that can deliver results in 15 minutes. It released a rapid test in March called the ID Now that has been used by the White House. It also makes lab-based diagnostic tests and antibody tests.

Abbott has a $750 million contract with the U.S. government to sell it 150 million BinaxNOW tests. Most will be distributed to states for use in schools and other essential tasks.

The company said it expects 2020 adjusted profit per share to be at least $3.55 from continuing operations, up from its prior estimate of at least $3.25 per share.

Abbott's shares were down 3.2% at $104.86.

SVB Leerink's Danielle Antalffy said the stock's modest underperformance could be because the company implied that some of the COVID-driven upside or benefit would be reinvested in the business.

(Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Arun Koyyur and Tom Brown)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.43% 111.63 Delayed Quote.1.95%
BECTON, DICKINSON AND COMPANY -0.01% 240.25 Delayed Quote.-3.98%
ROCHE HOLDING AG -0.07% 348.2 Delayed Quote.12.75%
All news about ROCHE HOLDING AG
06/17ROCHE HOLDINGS AG  : Deutsche Bank reiterates its Neutral rating
06/17Synlogic, Roche in Bowel-Disease Collaboration
06/17ROCHE  : Syncona CFO to Retire; Three New Executives Named
06/17ROCHE  : Check You Employment Agreement's Restrictive Covenant
06/16WALL STREET STOCK EXCHANGE : How yesterday’s data could affect Fed policy
06/16Atea Pharma Hits Development Milestone for Covid-19 Treatment
06/16ROCHE  : Atea Pharmaceuticals Announces Achievement of AT-527 Development Milest..
06/16ROCHE  : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage T..
06/15ELOXX PHARMACEUTICALS  : Roche Discloses 5.3% Stake in Eloxx Pharmaceuticals
06/15ROCHE HOLDINGS AG  : Berenberg reaffirms its Neutral rating
More news
Sales 2021 60 592 M 65 971 M 65 971 M
Net income 2021 14 612 M 15 909 M 15 909 M
Net cash 2021 4 915 M 5 351 M 5 351 M
P/E ratio 2021 20,3x
Yield 2021 2,69%
Capitalization 301 B 329 B 328 B
EV / Sales 2021 4,89x
EV / Sales 2022 4,75x
Nbr of Employees 101 465
Free-Float 83,4%
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 355,40 CHF
Last Close Price 348,40 CHF
Spread / Highest target 25,7%
Spread / Average Target 2,01%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG12.75%328 768
JOHNSON & JOHNSON4.98%435 090
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939